Orchard's portfolio of ex vivo, autologous, hematopoietic stem cell (HSC) based gene therapies includes Strimvelis, a gammaretroviral vector-based gene therapy and the first such treatment approved by the European Medicines Agency for severe combined immune deficiency due to adenosine deaminase
Cordycepin has demonstrated potent anti-cancer activity in multiple preclinical studies, but has not been successfully developed primarily due to its degradation by the enzyme adenosine deaminase
. Unlike the parent nucleoside analogue, NUC-7738 is not a substrate for this enzyme and is therefore resistant to degradation by ADA.
In blood samples of dogs with visceral leishmaniasis, levels of malondialdehyde, total antioxidant capacity, glutathione, nitric oxide, myeloperoxidase, adenosine deaminase
and cytokines (TNF-alpha, IL-1[beta]) were determined and compared with the healthy controls.
Plants produce phytostimulators which increase the growth of plants, mostly cytokinins, indole-3-acetic acid (IAA), gibberellins, auxins and ACC deaminase
(Abbamondi et al., 2016).
CSF Adenosine Deaminase
and its Role in Tuberculous Meningitis
The following information was recorded: age of patient (excluded from study if <18 years), gender, HIV status if noted in the report, adequacy of specimen submitted, histopathological diagnosis made and pleural fluid adenosine deaminase
(ADA) result, as well as Ziehl-Neelsen (ZN) stain result if noted on the final report.
Objective: To find out the association of Cerebrospinal Fluid (CSF) adenosine deaminase
(ADA) Levels with tuberculosis meningitis.
In terms of application, the global market has been divided into ophthalmology, oncology, and adenosine deaminase
?deficient severe combined immunodeficiency (ADA-SCID).
Objective: To determine diagnostic accuracy of Cerebro Spinal Fluid (CSF) Adenosine DeAminase
(ADA) in detecting Tuberculous Meningitis (TBM) keeping CSF Polymerase Chain Reaction (PCR) for Mycobacterium Deoxy Ribonucleic Acid (DNA) as gold standard.
Developed using the i-DPS technology, APS001F, a recombinant Bifidobacterium to express Cytosine Deaminase
which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is under a phase 1 clinical trial in the US, added Anaeropharma.
received approval for Revcovi, an enzyme injection for the treatment ofadenosine deaminase
severe combined immune deficiency in pediatric and adult patients, the company announced Friday.
The leading development product using i-DPS technology, APS001F, a recombinant Bifidobacterium to express Cytosine Deaminase
which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is under a phase 1 clinical trial in the U.S.